Abstract
Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4%) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9%) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.
| Original language | English |
|---|---|
| Pages (from-to) | 1582-1585 |
| Number of pages | 4 |
| Journal | Acta Paediatrica, International Journal of Paediatrics |
| Volume | 95 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 1 2006 |
Fingerprint
Keywords
- Anti-HAV vaccine
- Immunization
- Infants
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose. / De Silvestri, Annalisa; Zara, Francesca; Terulla, Virginio; Brerra, Roberto; Zucca, Silvana; Belloni, Cesare.
In: Acta Paediatrica, International Journal of Paediatrics, Vol. 95, No. 12, 01.12.2006, p. 1582-1585.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose
AU - De Silvestri, Annalisa
AU - Zara, Francesca
AU - Terulla, Virginio
AU - Brerra, Roberto
AU - Zucca, Silvana
AU - Belloni, Cesare
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4%) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9%) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.
AB - Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4%) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9%) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.
KW - Anti-HAV vaccine
KW - Immunization
KW - Infants
UR - http://www.scopus.com/inward/record.url?scp=33845260084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845260084&partnerID=8YFLogxK
U2 - 10.1080/08035250600615119
DO - 10.1080/08035250600615119
M3 - Article
C2 - 17129966
AN - SCOPUS:33845260084
VL - 95
SP - 1582
EP - 1585
JO - Acta Paediatrica, International Journal of Paediatrics
JF - Acta Paediatrica, International Journal of Paediatrics
SN - 0803-5253
IS - 12
ER -